ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2768

Patient Reported Outcomes and Acute Phase Reactants in  Polymyalgia Rheumatica in Patients Treated with Prednisone Versus Modified-Release Prednisone

Mauro Betelli, Giulia Erba, Massimo Ricci, Carlo Valena, Elisabetta Allevi, Marta Riva, Giorgia Grosso, Simona Barbarossa, Federica Bonomi and Maria Rosa Pozzi, Department of Internal Medicine, Rheumatology Outpatient Clinic - San Gerardo Hospital – Milano-Bicocca University, Monza, Italy

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Outcome measures, polymyalgia rheumatica and prednisolone, prednisone

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Vasculitis

Session Type: Abstract Submissions (ACR)

Background/Purpose

Polymyalgia rheumatica (PMR) is a chronic inflammatory disorder of the elderly, characterised by morning stiffness, pain and aching in the hip and shoulder girdles and acute phase reactants increase. The response to low-dose prednisone (Pd) is marked and fast on both Patient Reported Outcomes (PROs) and acute phase reactants, but most patients require a treatment course of 1–3 years. A new modified-release delivery system Prednisone adapts the release of the administered glucocorticoid to the circadian rhythms and proved to be useful for morning stiffness, fatigue and disease activity control in Rheumatoid Arthritis. We compared Prednisone (Pd) to modified release Prednisone (MR-Pd) on PROs and acute phase reactants in Polymyalgia Rheumatica.

Methods

We studied 15 patients (5 men, mean age 70 years, SD 8.25) with newly diagnosed PMR and previously untreated. They received the same tapering dose of prednisone starting from 15 mg: 8 patients received a MR-Pd tablet, and 7 a Pd tablet. We observed no drop-outs but only ten patients have completed the 16-week assessment period by now (3 men, mean age 72 years, SD 5.48). CRP/ESR, VAS for stiffness duration/intensity  and fatigue and HAQ-DI (PROs) were obtained at baseline and at week 4 and 16. We used Standardized Response Means (SRM), a measure of responsiveness, to evaluate acute phase response and clinical parameters improvement at week 4 and 16.

Results

The mean relative changes of the CRP/ESR and PROs from baseline to 4th and 16th week were not statistically different between Pd and MR-Pd (p > 0.05), confirming their same efficacy at the same dosage. We noticed that after 4 weeks CRP, fatigue, stiffness duration and HAQ assessment showed a better response in the group treated with modified release CS (CRP SRM 1.03-0.71, fatigue SRM 1.25-0.80; stiffness duration 1.40–0.40, HAQ SRM 1.74-1.10 for modified and immediate release Prednisone respectively). However at week 16 there were no significantly differences between CRP and HAQ (SRM 0.56 – 0.67 and 1.83 – 1.82 respectively), whereas fatigue and stiffness duration improved in patients treated with Pd (SRM 1.12- 7.03 and 0.72 – 1.01). Otherwise impact on stiffness intensity was constantly better in patients treated with Pd (after 4 and 16 weeks respectively: SRM 1.70-1.15 and 4.19-1.16).

Conclusion

Modified-Release Prednisone and Prednisone showed the same overall efficacy on Patient Reported Outcomes and acute phase reactants in patients with PMR, but with different timings and impacts on various disease aspects.


Disclosure:

M. Betelli,
None;

G. Erba,
None;

M. Ricci,
None;

C. Valena,
None;

E. Allevi,
None;

M. Riva,
None;

G. Grosso,
None;

S. Barbarossa,
None;

F. Bonomi,
None;

M. R. Pozzi,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patient-reported-outcomes-and-acute-phase-reactants-in-polymyalgia-rheumatica-in-patients-treated-with-prednisone-versus-modified-release-prednisone/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology